BC Week In Review | Mar 26, 2007
Clinical News

Talvesta talotrexin: Suspended Phase I/II enrollment

HNAB suspended enrollment in the Phase II portion of an open-label, U.S. Phase I/II trial after incidences of leukoencephalopathy, including one patient who died, were seen in the Phase I trial portion. HNAB said no...
BC Extra | Mar 24, 2007
Clinical News

Hana off on pipeline update

HNAB fell $1.31 (35%) to $2.41 on a newsy Friday that saw the company pull an NDA for one compound, suspend development of another and update its development plans for a third. HNAB is withdrawing...
BC Week In Review | Nov 13, 2006
Clinical News

Talvesta talotrexin: Phase I data

In a dose-escalation Phase I trial in 25 patients, 54 mg/m 2 was the MTD of Talvesta. At that dose, the compound had a mean peak plasma concentration of 17.42 ng/L and the mean plasma...
BC Week In Review | Nov 6, 2006
Clinical News

Talvesta talotrexin: Phase I/II started

HNAB began the Phase II portion of an ongoing open-label Phase I/II trial of Talvesta. The Phase II portion will focus on complete remission rates in relapsed or refractory ALL patients . Data from the Phase...
BC Week In Review | Sep 25, 2006
Clinical News

Talvesta talotrexin: Phase I/II start

Next quarter, HNAB will begin the Phase I portion of an open-label, Phase I/II trial. In the Phase I portion, 15-20 patients with solid tumors will receive Talvesta once every 3 weeks. Pending positive data,...
BC Week In Review | Sep 25, 2006
Clinical News

Talvesta talotrexin: Suspended Phase I/II enrollment

HNAB suspended the open-label, international Phase II portion of a Phase I/II trial after Talvesta was associated with an incidence of mucositis and myelosuppression in about 8% of the 32 patients enrolled. Patients received twice-weekly...
BioCentury | Sep 25, 2006
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 9/22 cls Alnylam (ALNY) ThinkEquity Andrew McDonald Discontinued NA -9% $13.18 The firm dropped coverage of the infectious disease and...
BioCentury | Sep 25, 2006
Product Development

NSCLC pipeline

NSCLC pipeline NSCLC pipeline Clinical stage compounds for non-small cell lung cancer that remain unpartnered after the licensing deal between Novartis and Cell Therapeutics for Xyotax. (A) Phase II portion halted last week NSCLC as...
BC Extra | Sep 20, 2006
Clinical News

Hana down on stopped Talvesta Phase II

On Tuesday, HNAB was down $0.35 to $7.18 following an annoucement late Monday that it suspended the Phase II portion of a Phase I/II trial of Talvesta talotrexin (PT-523) to treat patients with relapsed or...
BioCentury | Jun 5, 2006
Product Development

ALL/CML pipeline

ALL/CML pipeline ALL/CML pipeline Selected therapeutics in clinical development for acute lymphoblastic leukemia (ALL) and/or chronic myelogenous leukemia (CML). (A) Already marketed for ALL patients who are hypersensitive to native L-asparaginase; (B) In-licensed exclusive worldwide...
Items per page:
1 - 10 of 24